Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the prevention of traveller's diarrhoea.

Authors:
Address: International Vaccination Centre of Malaga, Ministry of Health, Subdelegation in Malaga, Paseo Marítimo Pablo Ruiz, Picasso 43, 29017 Málaga, Spain. rosamaria.lopez@map.es
Journal:

Publication:

abstract

BACKGROUND:

Nowadays there is a debate about the indication of the oral whole-cell/recombinant B-subunit cholera vaccine (WC/rbs) in traveller's diarrhoea. However, a cost-benefit analysis based on real data has not been published.

METHODS:

A cost-Effectiveness and cost-benefit study of the oral cholera vaccine (WC/rBS), Dukoral for the prevention of traveller's diarrhoea (TD) was performed in subjects travelling to cholera risk areas. The effectiveness of WC/rBS vaccine in the prevention of TD was analyzed in 362 travellers attending two International Vaccination Centres in Spain between May and September 2005.

RESULTS:

The overall vaccine efficacy against TD was 42,6%. Direct healthcare-related costs as well as indirect costs (lost vacation days) subsequent to the disease were considered. Preventive vaccination against TD resulted in a mean saving of 79.26 euro per traveller.

CONCLUSION:

According to the cost-benefit analysis performed, the recommendation for WC/rBS vaccination in subjects travelling to zones at risk of TD is beneficial for the traveller, regardless of trip duration and visited continent.

Related Articles
Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS.
Travel Med Infect Dis. 2007
Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS.
López-Gigosos R, García-Fortea P, Reina-Doña E, Plaza-Martín E. Travel Med Infect Dis. 2007 Nov; 5(6):380-4. Epub 2007 Jul 30.
Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea.
J Travel Med. 2009
Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea.
Lundkvist J, Steffen R, Jönsson B. J Travel Med. 2009 Jan-Feb; 16(1):28-34.
Reduction of travellers' diarrhoea by WC/rBS oral cholera vaccine in young, high-risk travellers.
Vaccine. 2009
Reduction of travellers' diarrhoea by WC/rBS oral cholera vaccine in young, high-risk travellers.
Torrell JM, Aumatell CM, Ramos SM, Mestre LG, Salas CM. Vaccine. 2009 Jun 19; 27(30):4074-7. Epub 2009 May 3.
Review Oral cholera vaccines: use in clinical practice.
Lancet Infect Dis. 2006
Review Oral cholera vaccines: use in clinical practice.
Hill DR, Ford L, Lalloo DG. Lancet Infect Dis. 2006 Jun; 6(6):361-73.
Review Oral cholera vaccine--for whom, when, and why?
Travel Med Infect Dis. 2006
Review Oral cholera vaccine--for whom, when, and why?
Topps MH. Travel Med Infect Dis. 2006 Jan; 4(1):38-42.
Vaccination strategies to combat an infectious globe: oral cholera vaccines.
J Glob Infect Dis. 2011
Vaccination strategies to combat an infectious globe: oral cholera vaccines.
López-Gigosos RM, Plaza E, Díez-Díaz RM, Calvo MJ. J Glob Infect Dis. 2011 Jan; 3(1):56-62.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.